ID   YCC-9
AC   CVCL_9664
SY   YCC9
DR   cancercelllines; CVCL_9664
DR   GEO; GSM552390
DR   GEO; GSM562411
DR   GEO; GSM1237689
DR   GEO; GSM1237714
DR   Progenetix; CVCL_9664
DR   Wikidata; Q54995344
RX   PubMed=18922971;
RX   PubMed=29435981;
CC   From: Yonsei Cancer Center; Seoul; South Korea.
CC   Population: Korean.
CC   Doubling time: 35 hours (PubMed=29435981).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C4004; Gastric adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   64Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 10-04-25; Version: 14
//
RX   PubMed=18922971; DOI=10.1158/1541-7786.MCR-08-0166;
RA   Yu E.J., Lee Y., Rha S.Y., Kim T.S., Chung H.C., Oh B.K., Yang W.I.,
RA   Noh S.H., Jeung H.-C.;
RT   "Angiogenic factor thymidine phosphorylase increases cancer cell
RT   invasion activity in patients with gastric adenocarcinoma.";
RL   Mol. Cancer Res. 6:1554-1566(2008).
//
RX   PubMed=29435981; DOI=10.1002/ijc.31304;
RA   Kim H.J., Kang S.K., Kwon W.S., Kim T.S., Jeong I., Jeung H.-C.,
RA   Kragh M., Horak I.D., Chung H.C., Rha S.Y.;
RT   "Forty-nine gastric cancer cell lines with integrative genomic
RT   profiling for development of c-MET inhibitor.";
RL   Int. J. Cancer 143:151-159(2018).
//